Drug Trial Radar · NCT07643623
Neoadjuvant and Adjuvant Therapy Studies of Sintilimab Combined With Chemotherapy With or Without Ipilimumab N01 in Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
Last checked: Nov 19, 2026Latest source record: Aug 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
720
Planned (sponsor's estimate)
Start
Jul 31, 2026
Primary completion
Dec 31, 2031
Study completion Dec 31, 2031
Sponsor
- Lead sponsor
- Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.Industry
- Sponsor type
- Industry
- First posted
- Jun 11, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Randomized, Double-Blind, Phase II/III Clinical Study of the Efficacy and Safety of Sintilimab Combined with Chemotherapy With or Without Ipilimumab N01 in Perioperative Treatment of Resectable Gastric/Gastroesophageal Junction Adenocarcinoma.
Conditions
- Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
Interventions
tegafur, Gimeracil and Oteracil Potassium CapsulesDrug
40mg/m2, D1-14 BID PO Q3W
Sintilimab PlaceboDrug
200 mg, D1 IV Q3W
SintilimabDrug
200mg D1 IV Q3W
Ipilimumab N01Drug
1mg/kg, D1 IV Q6W
Oxaliplatin for injectionDrug
130 mg/m2 D1 IV Q3W
Ipilimumab N01 PlaceboDrug
1mg/kg, D1 IV Q6W
Primary outcomes
What the sponsor says the trial is designed to measure.
- Major Pathological Response (MPR) rate in Resectable Gastric/Gastroesophageal Junction AdenocarcinomaTime frame: Up to approximately 6 weeks following the beginning of Post-operative Assessment baseline(up to Study 2 years )
- Event-Free Survival (EFS)Time frame: Up to approximately 5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.